Karamvir Yadav: Thromboembolism in Cancer Trials, Underestimated Risk
Karamvir Yadav/X

Karamvir Yadav: Thromboembolism in Cancer Trials, Underestimated Risk

Karamvir Yadav, Medical Oncologist in Jaipur, India, shared a post on X:

“Nice informative article on Journal of Clinical Oncology.

Thromboembolism in cancer trials may be significantly underestimated.

  • RCTs: VTE often <3%
  • Real-world: >10%

Better reporting of VTE and ATE, longer follow-up, and real-world data are critical to improve patient safety and prevention.”Karamvir Yadav: Thromboembolism in Cancer Trials, Underestimated Risk

Title: Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action

Authors: David Calverley, Avi Leader, May Anne Cheong, Kristen Sanfilippo, Ginny Mason, Gary Lyman, Nicole Kudere

Read the Full Article.

Karamvir Yadav: Thromboembolism in Cancer Trials, Underestimated Risk

Other articles featuring Karamvir Yadav on OncoDaily.